Antinuclear Antibody Test Market Trends

  • Report ID: 4133
  • Published Date: Sep 09, 2025
  • Report Format: PDF, PPT

Antinuclear Antibody Test Market - Growth Drivers and Challenges

Growth Drivers

  • Rising Prevalence of Autoimmune Diseases Among the Global Population – The increasing number of people suffering from autoimmune disorders is estimated to boost the market growth in the coming years. The percentage raise of autoimmune diseases across the world in a year was found to be 4%-10% with the impact of many environmental factors. The increasing change in food habits, rising cholesterol levels, blood sugar levels, and less physical work are driving the market growth. The rising number of diabetic cases, rheumatoid arthritis, and multiple sclerosis is boosting the growth of the market in the coming years.  

  • Growing Geriatric Population Across the Globe with Less Immunity Strength – The elderly population in America by 2050 was estimated to reach more than 85 million with twice the population raising from its base of 40 million in just three decades.

  • Increasing the Healthcare Sector with Rising Importance on Health – The national healthcare expenditure of the U.S. is estimated to rise by 7% in the coming five years during 2022-2027 as per the observations.

  • Rising Number of Diagnostic Laboratories with Increasing Incidence of Diseases – According to the estimations, there are over 25,000 diagnostic and medical laboratories around the world in the U.S. as of 2023.

Challenges

  • Lack of Skilled Professionals who can Handle the Test Kits
  • Risk of Errors During the Diagnosis Process Causing False Positive and Negative Results
  • High Price of Lab Equipment – The laboratory equipment that are used for antinuclear antibody test are often quite high, as a result of which, it cannot be afforded by small laboratories in several developed and developing nations.

Base Year

2025

Forecast Period

2026-2035

CAGR

13.3%

Base Year Market Size (2025)

USD 1.88 billion

Forecast Year Market Size (2035)

USD 6.55 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of antinuclear antibody test is evaluated at USD 2.11 billion.

The global antinuclear antibody test market size was worth over USD 1.88 billion in 2025 and is poised to grow at a CAGR of around 13.3%, reaching USD 6.55 billion revenue by 2035.

North America antinuclear antibody test market will dominate over 40.6% share by 2035, fueled by rising autoimmune disease prevalence and aging population.

Key players in the market include F. Hoffmann-La Roche Ltd., ERBA Diagnostics, Inc., Zeus Scientific Inc., Trinity Biotech plc, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Immuno Concepts Inc., Euroimmun Medizinische Labordiagnostika AG, Antibodies Incorporated, Becton, Dickinson and Company.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos